Wockhardt gets favourable recommendation from CDSCO for antibiotic for CABP
Wockhardt shares on Friday ended 5 per cent up at Rs 994.95 apiece on BSE. Representative image.
Drug firm Wockhardt on Friday said the national drug regulator has accorded a favourable recommendation for its novel antibiotic developed for the treatment of community-acquired bacterial pneumonia (CABP) in adults.
The Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO) has provided a favourable recommendation for Miqnaf (nafithromycin), the drug firm said in a statement.
Click here to connect with us on WhatsApp
The SEC recommendation is based on CDSCO’s comprehensive review of the product dossier consisting of non-clinical, US/EU Phase 1, Global Phase 2 and India Phase 3 clinical studies conducted over the last 15 years, it added.
A positive opinion from the SEC of CDSCO would pave the way for gaining DCGI’s final approval for Miqnaf, the company stated.
Miqnaf is the once-a-day 3-days-only treatment for CABP patients, including those caused by multi-drug resistant (MDR) bugs.
CABP is the most common infection, leading to hospitalisation and death. Globally, 2.4 million annual deaths are caused by lower respiratory tract infections.
India contributes to 23 per cent of the global community pneumonia burden, the drug firm said.
Wockhardt shares on Friday ended 5 per cent up at Rs 994.95 apiece on BSE.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
First Published: Oct 11 2024 | 8:09 PM IST